Lung-MAP aims for faster, more precise trials
This article was originally published in Scrip
Executive Summary
A much anticipated trial being run under a public-private partnership involving the US National Cancer Institute (NCI), five drug makers and a group of nonprofits using a "master protocol" approach finally for got underway on 16 June, with the goal of matching the most appropriate experimental drug to the right patient, which ultimately would improve and accelerate the clinical testing process, speeding new targeted medicines to the marketplace.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.